Shenzhen Bioeasy Biotechnology Co Ltd
Shenzhen Bioeasy Biotechnology Co Ltd develops and sells medical diagnostic products, including rapid test kits and related equipment, primarily serving the healthcare sector.
Business. Shenzhen Bioeasy Biotechnology Co Ltd (300942.SZ) is a healthcare services and equipment company engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the development and sale of medical devices and related consumables. Headquartered in Shenzhen, the company is primarily listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Shenzhen Bioeasy Biotechnology Co Ltd (300942.SZ) is a healthcare services and equipment company engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the development and sale of medical devices and related consumables. Headquartered in Shenzhen, the company is primarily listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
The company's capital structure is characterized by a debt-to-equity ratio of 0.5, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 5.09, suggesting strong short-term liquidity. However, the company has negative net cash after subtracting total debt, which raises concerns about its ability to meet long-term obligations without additional financing.
Profitability metrics show a return on equity (ROE) of 1.52% and a return on assets (ROA) of 0.9%, both of which are below the typical thresholds for high-performing firms in the medical equipment and supplies industry. The gross profit margin is 63.1%, which is relatively strong, but the operating margin is only 2.2%, indicating significant operating expenses relative to revenue.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases exposure to regional economic and regulatory risks.
Looking ahead, the company's revenue is projected to grow by 10.5% in the current fiscal year and 12.3% in the next fiscal year, based on the outlook provided. These growth rates are modest compared to the industry median of 18.2% for the current year and 20.1% for the next year, suggesting potential challenges in maintaining market share.
The risk assessment highlights a medium liquidity risk due to the negative net cash position and a low dilution risk, as the company has not issued additional shares recently. The key flag of negative net cash after total debt is a red flag for potential liquidity constraints.
Recent filings and transcripts indicate that the company is focusing on expanding its product line and entering new markets, particularly in emerging economies. However, there are no significant recent events that have materially impacted the company's financial performance or strategic direction.
- The company has a strong current ratio but faces liquidity risks due to negative net cash after total debt.
- Profitability metrics are below industry medians, indicating operational inefficiencies.
- Revenue growth projections are modest compared to industry benchmarks.
- The company's business is concentrated in a single segment with no geographic diversification.
- There is a low risk of dilution, but the company may need to secure additional financing to support its growth initiatives.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Shenzhen Bioeasy Biotechnology Co Ltd Market data — financials · 2026-05-26